Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Add‐on felbamate vs placebo

Adverse effects · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 236 participants
Very low

Add‐on felbamate vs placebo

Quality of life · people with drug‐resistant focal epilepsy

1 finding from 1 review

Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

Weekly paclitaxel vs three‐weekly paclitaxel

Overall survival · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.94 [0.66, 1.33]
2 studies · 263 participants
Very low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Overall survival · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.97 [0.77, 1.23]
1 study · 330 participants
Low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Response rate · women with recurrent epithelial ovarian cancer

It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.86 [0.4, 1.89]
1 study · 265 participants
Very low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.6 [0.39, 0.93]
1 study · 213 participants
Low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer

It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.34 [0.7, 2.57]
1 study · 52 participants
Very low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Progression‐free survival · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 1.07 [0.88, 1.3]
1 study · 330 participants
Low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Neurotoxicity · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel probably leads to lower neurotoxicity compared with 250 mg/m2 paclitaxel (moderate certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.41 [0.21, 0.8]
1 study · 330 participants
Moderate

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Neutropenia · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.14 [0.74, 1.74]
1 study · 330 participants
Low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Overall survival · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in overall survival compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.96 [0.77, 1.19]
1 study · 407 participants
Low

Weekly paclitaxel vs three‐weekly paclitaxel

Response rate · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes response rate compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.07 [0.78, 1.48]
2 studies · 263 participants
Very low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Response rate · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in response rate compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.75 [0.48, 1.17]
1 study · 382 participants
Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Progression‐free survival · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 1.09 [0.94, 1.28]
1 study · 407 participants
Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Neurotoxicity · women with recurrent epithelial ovarian cancer

135 mg/m2 paclitaxel showed no clear difference in neurotoxicity compared with 175 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.19 [0.01, 3.99]
1 study · 391 participants
Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Alopecia ‐ not measured · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found